Welcome to our dedicated page for Scopus Biopharma news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on Scopus Biopharma stock.
Scopus Biopharma Inc. (SCPS) is an innovative biopharmaceutical company developing cutting-edge therapies for diseases with critical unmet needs. This dedicated news hub provides investors and industry professionals with essential updates on clinical trials, strategic partnerships, and therapeutic advancements.
Access timely information about SCPS's progress in immuno-oncology treatments, antiviral therapies, and regenerative medicine development. Our curated news collection features verified updates on trial milestones, research collaborations with leading institutions, and financial developments impacting the company's trajectory.
Key updates include progress reports on cancer treatment candidates, partnership announcements with academic research centers, and analyses of the company's financial position. Bookmark this page to stay informed about SCPS's contributions to biopharmaceutical innovation and their pursuit of transformative medical solutions.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the appointment of Alan Horsager, Ph.D., as President following its acquisition of Olimmune Inc., an immunotherapy firm. Horsager will oversee the integration of Scopus and Olimmune's capabilities, focusing on their combined immuno-oncology pipeline, which includes promising bifunctional STAT3 inhibitors for cancer treatment. Chairman Joshua R. Lamstein expressed confidence in Horsager’s expertise to enhance shareholder value through innovative approaches in targeting STAT3, a key area in cancer therapy.
Scopus BioPharma (Nasdaq: SCPS) announced its acquisition of Olimmune, enhancing its position in the field of oligonucleotide cancer therapeutics. Olimmune specializes in oligonucleotide immunotherapies for cancer treatment, with a focus on its lead drug OLIM-01 targeting genitourinary and head and neck cancers. The acquisition underscores Scopus' aim to address traditionally 'undruggable' targets, positioning it as a global leader in the field. The financial terms of the acquisition remain undisclosed, but the integration is expected to leverage combined assets for significant advancements in immuno-oncology.
Scopus BioPharma (Nasdaq: SCPS) announced the rescheduling of its 2021 Annual Meeting of Stockholders to October 8, 2021. To propose business or director nominations, stockholders must notify the company by June 10, 2021, with proposals for inclusion in the proxy statement due by June 25, 2021. The meeting will address the company's lead drug candidate, a novel targeted immuno-oncology RNA therapy for cancer treatment. Stockholders can obtain proxy materials free from the SEC or the company's website.
Scopus BioPharma Inc. (Nasdaq: SCPS) has announced the rescheduling of its 2021 Annual Meeting of Shareholders, previously set for July 16, 2021. The new date, time, and location will be confirmed by the Scopus Board of Directors. The company, focused on innovative therapeutics for serious diseases, is developing a novel immuno-oncology RNA therapy for cancer and other serious conditions. Investors are advised to stay updated through the company's forthcoming proxy statement and documentation, which will contain crucial information about the meeting.
Scopus BioPharma (Nasdaq: SCPS) has received FDA approval for an investigational new drug application for its unique immuno-oncology RNA therapy, CpG-STAT3siRNA. This therapy targets multiple cancers and a Phase 1 clinical trial for B-cell non-Hodgkin lymphoma will commence at City of Hope. The innovative therapy combines RNA therapy with immunotherapy, using a TLR9 agonist to enhance immune response in tumors. The firm's focus on groundbreaking therapies aims to address significant medical needs, positioning SCPS for potential market growth.
Scopus BioPharma Inc. (Nasdaq: SCPS) has submitted an investigational new drug application (IND) to the FDA for its immuno-oncology RNA therapy targeting multiple cancers. This IND filing paves the way for a Phase 1 clinical trial focused on B-cell non-Hodgkin lymphoma at City of Hope. Chairman Joshua R. Lamstein emphasized the significance of this milestone, which he believes will enhance shareholder value. The drug candidate combines RNA therapy and immunotherapy, showcasing potential for effective cancer treatment.
Scopus BioPharma Inc. (Nasdaq: SCPS) has finalized the arrangements for the investigational new drug (IND) package for its lead drug candidate. The IND submission to the FDA is anticipated in Q2 2021. The company's lead candidate is a novel immuno-oncology gene therapy aimed at multiple cancers, uniquely combining gene therapy and immunotherapy. Chairman Joshua R. Lamstein highlights this IND submission as a critical milestone expected to drive shareholder value. Scopus is also developing new chemical entities for other serious diseases with significant unmet needs.
Scopus BioPharma (Nasdaq: SCPS) has successfully closed the underwriters' over-allotment option, raising total proceeds of $10.35 million from its follow-on public offering. The funds will primarily support the development of its lead drug candidate, a targeted immuno-oncology gene therapy for multiple cancers. The company aims to enhance this treatment in combination with checkpoint inhibitors. The offering statement was filed with the U.S. SEC on January 26, 2021.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced that underwriters fully exercised their over-allotment option, increasing total proceeds from its follow-on public offering to $10.35 million. This closing is expected on or about February 10, 2021. The funds will primarily be used for the development of the company's lead drug candidate, a novel immuno-oncology gene therapy targeting multiple cancers. The offering statement was filed with the SEC on January 26, 2021.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the closing of a $9 million follow-on public offering, successfully issuing 1,000,000 shares at $9.00 per share. The company also granted underwriters a 45-day option to purchase up to 150,000 additional shares. Proceeds from this offering will primarily be used to further develop its lead drug candidate, a targeted immuno-oncology gene therapy aimed at treating multiple cancers. The offering statement was filed with the U.S. Securities and Exchange Commission and became qualified on January 26, 2021.
